Abstract
The current study described the synthesis of novel low dose PVA capped Etoricoxib (ET) and montelukast (MT) conjugated Zinc Oxide (ZnO) nanomaterials (NMs) as potential anti-inflammatory, analgesic and antipyretic agents. A facile coprecipitation protocol was used for synthesis of NMs by combination of ET, MT and ZnO NP. The efficient synthesis of ET and MT conjugated ZnO NMs were confirmed through UV–visible, XRD, FTIR and DLS analysis. Data of in vivo anti-inflammatory activity indicated that potency of ZnO NMs was found to be greater than drugs (ET and MT). Analgesic potency of NMs was much higher than that of drugs (ET and MT). The in vivo antipyretic activity indicates that the results of NMs and drugs (ET and MT) are of similar effect but that of NMs are more potent based on per weight basis. A wide therapeutic window was shown by the acute toxicity study carried out via LD50 method. It is concluded that the novel low dose PVA capped ET and MT conjugated ZnO NMs were potential analgesic, antipyretic and anti-inflammatory agents.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
